dr. tagawa on remaining questions with psma-targeted radionuclide therapy in mcrpc
Published 4 years ago • 119 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
3:02
unanswered questions in psma-targeted radionuclide therapy
-
2:29
dr. tagawa on brca2 in patients with prostate cancer receiving psma-targeted radionuclide therapy
-
1:49
dr. tagawa on preliminary data with 225ac-j591 in mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
7:17
scott tagawa, md, on psma targeting in prostate cancer treatment
-
1:40
dr. tagawa on targeting psma in prostate cancer
-
1:31
dr. tagawa discusses agents targeted against psma
-
3:25
scott tagawa, md, discusses the results of phase i dose-escalation study regarding mcrpc
-
1:02
dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
-
3:07
psma-trt, 225ac-j591 and 177lu-psma i&t in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
2:08
scott tagawa md, considers next steps in the development of the psma-targeted alpha emitter in mcrpc
-
1:21
scott tagawa, md, on promising psma products in development for prostate cancer treatment
-
4:48
vision: lu-177-psma-617 in mcrpc
-
5:28
psma imaging: vision trial with dr. scott tagawa
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
2:13
dr. gafita on the opportunity for 177lu-psma-617 in mcrpc
-
7:26
targeting psma in mcrpc
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc